Paul Hessler

TL;DR: The results demonstrate the feasibility of using small molecule inhibitors to selectively target the catalytic activity of histone acetyltransferases, which may provide effective treatments for transcriptional activator-driven malignancies and diseases.

TL;DR: ABBV-744, a selective inhibitor of the BD2 domains of BET family proteins, is effective against prostate cancer in mouse xenograft models, with lower toxicities than the dual-bromodomain BET inhibitor ABBV -075 and underscores the potential value of selectively targeting theBD2 domain of BETfamily proteins for cancer therapy.

TL;DR: It is suggested that PTP1B inhibitors might be efficacious in the treatment of obesity by increasing leptin sensitivity and indicating that P TP1B is a negative regulator of leptin signaling.

TL;DR: This study identified numerous changes in multiple resistant lines; the changes were neither mutually exclusive nor universal across the cell lines tested, thus exemplifying the complexity and heterogeneity of potential resistance mechanisms.

TL;DR: It is demonstrated that apoptosis resulting from a loss in MCL-1 function requires expression of the proapoptotic protein BAK, and substantial synergy is demonstrated between navitoclax and Mcl-1 siRNA, the direct M CL-1 inhibitor A-1210477, or the indirect MCL -1 inhibitor flavopiridol, highlighting the therapeutic potential for inhibiting BCL-XL and MCL,1 in breast cancer.